^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lifyorli (relacorilant)

    i
    Other names: CORT125134, CORT-125134, CORT 125134
    Company:
    Corcept Therap
    Drug class:
    GCR antagonist
    Related drugs:
    2d
    Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer (clinicaltrials.gov)
    P1, N=42, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    Xtandi (enzalutamide) • Lifyorli (relacorilant)
    29d
    Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, University of Chicago | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • Lifyorli (relacorilant)
    1m
    Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, Corcept Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Lifyorli (relacorilant)
    2ms
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • Lifyorli (relacorilant)
    2ms
    Gynecologic cancers in 2025: a year in review. (PubMed, Int J Gynecol Cancer)
    In advanced ovarian cancer, TRUST re-examined surgical timing, supporting primary cytoreduction in selected resectable patients, whereas ICON8B suggested that weekly paclitaxel with carboplatin and bevacizumab may improve outcomes in high-risk disease. Platinum-resistant ovarian cancer saw the most disruptive progress: mirvetuximab soravtansine validated folate receptor-α as a therapeutic target, with overall survival benefit in high-expressing tumors; trastuzumab deruxtecan expanded actionable HER2 disease, with greatest activity in tumors rated 3+ by immunohistochemistry; and combination strategies, including relacorilant plus nab-paclitaxel and pembrolizumab plus weekly paclitaxel ± bevacizumab, delivered clinically meaningful survival signals, underscoring the need for harmonized biomarker strategies and proactive toxicity mitigation...In cervical cancer, pembrolizumab added to definitive chemoradiotherapy set a new benchmark in locally advanced disease, and ultra-sensitive circulating tumor DNA analyses emerged as a powerful prognostic tool to enable post-treatment risk-adapted strategies. Collectively, the 2025 data set reinforces a "right therapy, right patient, right time" paradigm and prioritizes confirmatory antibody-drug conjugate trials, resistance biology, and dynamic biomarkers to translate gains into durable, equitable benefit.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • albumin-bound paclitaxel • Elahere (mirvetuximab soravtansine-gynx) • Lifyorli (relacorilant)
    4ms
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • Lifyorli (relacorilant)
    5ms
    BELLA: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=270, Recruiting, Corcept Therapeutics | N=90 --> 270
    Enrollment change
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • Lifyorli (relacorilant)
    11ms
    Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=178, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
    Trial completion • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    albumin-bound paclitaxel • Lifyorli (relacorilant)
    11ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • Lifyorli (relacorilant)
    1year
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • Lifyorli (relacorilant)
    1year
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial primary completion date: Mar 2026 --> Mar 2025
    Trial primary completion date
    |
    albumin-bound paclitaxel • Lifyorli (relacorilant)
    1year
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    albumin-bound paclitaxel • Lifyorli (relacorilant)